The US Food and Drug Administration has granted Aidoc's new AI chest X-ray analysis system a 'breakthrough device' designation, according to Israeli media. The designation, the company's second in less than a year, accelerates regulatory approval for a system designed to auto-generate radiology report drafts and reduce radiologist workload.
Israeli artificial-intelligence company Aidoc has received a second "breakthrough device" designation from the US Food and Drug Administration in less than a year, according to an N12 report published Thursday. The designation applies to a new system that analyzes chest X-rays and automatically generates draft radiology reports, intended to shorten interpretation times and ease radiologist workloads. Aidoc, based in Tel Aviv, develops AI-powered medical imaging tools. The FDA's breakthrough device program is designed to accelerate the development and review of technologies that offer more effective treatment or diagnosis for life-threatening or debilitating conditions. The company's previous breakthrough designation, reported by The Zioneer in February 2026, covered a different AI product. The specific timeline for full FDA clearance of the new system has not been disclosed.
- DevelopingGovernment approves national AI plan with quantum computer, public-sector integration
- DevelopingIsraeli company reveals most severe case of AI model 'distillation' exposed to date
- DevelopingIsrael reportedly considers US IPOs for major defense firms IAI and Rafael
- DevelopingSpaceX acquires Israeli-founded AI coding startup Cursor for $60 billion after IPO
Source and signal
- Internal intake